Loading...
XTSX
RX
Market cap99mUSD
Dec 05, Last price  
12.18CAD
1D
1.92%
1Q
2.96%
Jan 2017
52.25%
Name

Biosyent Inc

Chart & Performance

D1W1MN
XTSX:RX chart
P/E
18.96
P/S
3.94
EPS
0.64
Div Yield, %
1.11%
Shrs. gr., 5y
-3.27%
Rev. gr., 5y
10.33%
Revenues
35m
+10.89%
748,5201,514,4911,104,3251,101,9911,029,9021,681,2102,808,6665,024,1547,799,42612,211,12715,388,19617,922,27020,762,75521,527,02821,424,32422,332,16828,618,21827,925,18731,590,30235,030,897
Net income
7m
+12.54%
505,257383,145-125,991-287,892-260,55752,160420,3921,541,3171,928,0283,154,0793,764,8894,309,5055,206,2775,705,3864,369,2953,795,3356,281,5665,458,3456,460,1277,270,104
CFO
9m
+71.39%
747,809222,25814,249-260,094-342,79237,892596,0791,249,1452,118,9343,640,0132,810,9204,399,0226,546,1316,286,5984,771,0236,894,4254,674,8884,948,7565,054,9748,663,484
Dividend
Sep 04, 20240.045 CAD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
IPO date
May 22, 1981
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT